GO:0004621 GPI anchor phospholipase D activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004621 (GPI anchor phospholipase D activity) catalyzes the hydrolysis of glycosylphosphatidylinositol (GPI) anchors on proteins, releasing phosphatidate and a glycoprotein inositol product.
• The enzyme responsible, GPI-specific phospholipase D (GPLD1), is a secreted protein that circulates in serum and associates with apolipoprotein complexes.
• GPLD1 activity is elevated in metabolic disorders such as diabetes and obesity, and it has been linked to chronic disease pathology.
• Overexpression of GPLD1 alters GPI metabolism and can affect the surface expression of GPI-anchored proteins.
• GPLD1 is posttranslationally modified, and its activity is regulated by proteolytic processing and complex formation.
• CRISPR-based models (knockout, knock-in, overexpression) are powerful tools to dissect GPLD1 function in health and disease.
Description
GPI anchor phospholipase D activity (GO:0004621) is a molecular function that cleaves the glycosylphosphatidylinositol (GPI) anchor attached to many cell-surface proteins. This activity releases proteins from the membrane and generates phosphatidate, a lipid second messenger. The enzyme responsible, GPI-specific phospholipase D (GPLD1), is unique in that it is secreted and found in serum, where it associates with lipoproteins. Understanding this activity is crucial because GPI-anchored proteins play roles in cell signaling, immune response, and development, and their dysregulation is implicated in metabolic and chronic diseases. Research into GO:0004621 has gained momentum due to its potential as a therapeutic target and biomarker in conditions such as diabetes and cardiovascular disease.
GPI anchor phospholipase D activity At A Glance
| GO ID | GO:0004621 |
|---|---|
| GO term | GPI anchor phospholipase D activity |
| Ontology | molecular_function |
| Synonym | glycoprotein-phosphatidylinositol phosphatidohydrolase activity; glycoprotein phospholipase D activity; glycosylphosphatidyl inositol-anchor protein phospholipase D activity; GPI-PLD activity |
| Major function | Cleavage of GPI anchors on proteins, releasing them from membranes and generating phosphatidate |
| Enzyme | GPI-specific phospholipase D (GPLD1) |
| Localization | Secreted; found in serum associated with lipoproteins |
| Substrates | GPI-anchored proteins |
| Products | Phosphatidate and glycoprotein inositol |
What Is GO:0004621?
GPI anchor phospholipase D activity (GO:0004621) is defined as the catalysis of the reaction: glycoprotein phosphatidylinositol + H2O = phosphatidate + glycoprotein inositol, by cleavage of the second phosphodiester bond between the phosphate and phospholipid. In simpler terms, it is an enzyme activity that cuts the GPI anchor that tethers certain proteins to the cell membrane, releasing the protein and producing phosphatidate.
Why Is GPI anchor phospholipase D activity Important in Cell Biology?
GPI anchor phospholipase D activity is important because it regulates the release of GPI-anchored proteins from cell membranes, influencing processes such as signal transduction, cell adhesion, and immune recognition. The enzyme GPLD1 is secreted into the bloodstream and its activity is altered in metabolic disorders, making it a potential biomarker and therapeutic target. Moreover, GPLD1 has been linked to aging and cognitive function, with studies showing that exercise-induced GPLD1 can reverse age-related memory loss. Thus, understanding GO:0004621 provides insights into basic cell biology and disease mechanisms.
• Regulates the surface expression and release of GPI-anchored proteins, affecting cell signaling and adhesion.
• GPLD1 activity is elevated in insulin-resistant states and obesity, linking it to metabolic syndrome.
• GPLD1 is associated with apoA-I and apoA-IV containing complexes, connecting it to lipid metabolism.
• Overexpression of GPLD1 alters GPI metabolism and can affect the localization of GPI-anchored proteins.
• GPLD1 is posttranslationally modified, and its activity can be regulated by proteolysis.
• GPLD1 has been implicated in chronic diseases such as diabetes, cardiovascular disease, and cancer.
• Exercise-induced GPLD1 from liver can improve brain function and neurogenesis in aged models.
• GPI anchor phospholipase D activity may serve as a therapeutic target for metabolic and neurodegenerative disorders.
What Happens During GPI anchor phospholipase D activity?
Substrate recognition and binding
In simple terms: The enzyme finds and attaches to the GPI anchor on a protein.
GPI-specific phospholipase D (GPLD1) recognizes and binds to the glycosylphosphatidylinositol (GPI) anchor attached to the C-terminus of target proteins. This binding is mediated by the enzyme's active site, which accommodates the phosphatidylinositol moiety of the GPI anchor. The enzyme is secreted and can act on GPI-anchored proteins either at the cell surface or in serum.
Catalytic cleavage of the GPI anchor
In simple terms: The enzyme cuts the anchor, releasing the protein.
GPLD1 catalyzes the hydrolysis of the second phosphodiester bond between the phosphate and the phospholipid of the GPI anchor, resulting in the release of the protein and the generation of phosphatidate and glycoprotein inositol. This cleavage is specific to GPI anchors and does not affect other phospholipids. The reaction requires water and is dependent on the enzyme's active site residues.
Product release and downstream effects
In simple terms: The products are released and can have their own effects.
Following cleavage, the GPI-anchored protein is released from the membrane, which can alter its function or localization. Phosphatidate, a lipid second messenger, can activate signaling pathways involved in cell growth and differentiation. The released glycoprotein inositol may be further metabolized or excreted.
Regulation of GPLD1 activity
In simple terms: The enzyme's activity is controlled by modifications and interactions.
GPLD1 is posttranslationally modified, and its activity can be regulated by proteolytic processing. It associates with apolipoprotein complexes in serum, which may modulate its substrate accessibility and activity. In metabolic disorders, GPLD1 activity is upregulated, suggesting regulation by metabolic factors.
Key Genes Involved in GO:0004621 GPI anchor phospholipase D activity
The following genes and proteins are key players in GPI anchor phospholipase D activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GPLD1 | Encodes GPI-specific phospholipase D, the enzyme responsible for GO:0004621 activity | Central to studies of GPI anchor cleavage and metabolic disease |
| PIGA | Involved in GPI anchor biosynthesis, providing substrate for GPLD1 | Mutations cause paroxysmal nocturnal hemoglobinuria; relevant to GPI anchor biology |
| PIGB | GPI anchor biosynthesis | Potential modifier of GPLD1 substrate availability |
| PIGC | GPI anchor biosynthesis | May affect GPI-anchored protein levels |
| PIGF | GPI anchor biosynthesis | Linked to GPI deficiency disorders |
| PIGG | GPI anchor biosynthesis | Mutations cause GPI deficiency |
| PIGK | GPI transamidase component | Required for attaching GPI anchors to proteins |
| PIGL | GPI anchor biosynthesis | Defects cause CHIME syndrome |
| PIGM | GPI anchor biosynthesis | Mutations cause GPI deficiency |
| PIGN | GPI anchor biosynthesis | Mutations cause multiple congenital anomalies |
| PIGO | GPI anchor biosynthesis | Mutations cause Mabry syndrome |
| PIGP | GPI anchor biosynthesis | Defects cause early epileptic encephalopathy |
| PIGQ | GPI anchor biosynthesis | Mutations cause epileptic encephalopathy |
| PIGS | GPI transamidase component | Required for GPI anchoring |
| PIGT | GPI transamidase component | Mutations cause GPI deficiency |
| PIGU | GPI transamidase component | Required for GPI anchoring |
| PIGV | GPI anchor biosynthesis | Mutations cause Mabry syndrome |
| PIGW | GPI anchor biosynthesis | Mutations cause GPI deficiency |
How Is GPI anchor phospholipase D activity Regulated?
GPLD1 activity is regulated at multiple levels. It is posttranslationally modified, and its activity can be modulated by proteolytic processing. In serum, GPLD1 associates with apolipoprotein complexes, which may influence its substrate specificity and activity. Metabolic states such as insulin resistance and obesity upregulate GPLD1 activity, suggesting regulation by metabolic hormones and nutrients. Additionally, exercise-induced factors can increase GPLD1 levels, linking its regulation to systemic physiology.
GPI anchor phospholipase D activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GPLD1 | Metabolic syndrome, insulin resistance | Gpld1 knockout mice on high-fat diet |
| GPLD1 | Aging-related memory loss | Gpld1 overexpression in aged mice |
| GPLD1 | Chronic diseases (cancer, cardiovascular) | Gpld1 knockout cell lines and xenografts |
| GPLD1 | Neurogenesis and cognition | Gpld1 transgenic mice with exercise intervention |
| GPLD1 | GPI metabolism | Gpld1 overexpression in cell culture |
Metabolic disorders
GPLD1 activity is elevated in metabolically deranged rats and humans, including those with diabetes and obesity. This upregulation may contribute to the pathophysiology of insulin resistance and cardiovascular disease. GPLD1 is also associated with apoA-I and apoA-IV containing complexes, linking it to lipid metabolism and atherosclerosis.
Neurodegeneration and aging
Exercise-induced GPLD1 from the liver has been shown to reverse aging- and Alzheimer's-related memory loss in mice by acting on the vasculature. Blood factors including GPLD1 transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. These findings suggest that GPLD1 and GPI anchor phospholipase D activity play a role in brain aging and neurodegeneration.
Chronic diseases
GPLD1 has been implicated in various chronic diseases, including cancer, cardiovascular disease, and diabetes. Its role in cleaving GPI-anchored proteins can affect cell signaling pathways that drive disease progression. Therefore, targeting GPLD1 activity may offer therapeutic benefits in chronic conditions.
From GPI anchor phospholipase D activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of GPLD1 loss on GPI-anchored protein surface expression? | GPLD1 knockout cell line (e.g., HEK293) |
| Does a specific point mutation in GPLD1 abolish its catalytic activity? | Point mutation knock-in in GPLD1 locus |
| How does GPLD1 overexpression affect metabolic phenotypes? | GPLD1 overexpression mouse model |
| What is the role of GPLD1 in exercise-induced neurogenesis? | GPLD1 knockout mice with exercise training |
| Can GPLD1 be used as a biomarker for metabolic disease? | Human serum samples from metabolically deranged patients |
| What is the interactome of GPLD1 in serum? | Tagged knock-in of GPLD1 followed by immunoprecipitation |
How to Study the GPI anchor phospholipase D activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GPI-PLD activity assay | Enzymatic cleavage of GPI anchors | Quantifying GPLD1 activity in serum or cell lysates |
| Western blot | GPLD1 protein levels and modifications | Assessing GPLD1 expression in tissues |
| Immunoprecipitation | Protein-protein interactions | Identifying GPLD1-associated complexes |
| CRISPR-Cas9 knockout | Loss of GPLD1 function | Studying the effects of GPLD1 depletion |
| CRISPR-Cas9 knock-in | Introduction of specific mutations | Modeling GPLD1 point mutations |
| Overexpression | Increased GPLD1 levels | Examining gain-of-function phenotypes |
| RNA-seq | Transcriptional changes | Identifying downstream pathways |
| Proteomics | Protein abundance and modifications | Discovering novel GPLD1 substrates or partners |
Enzymatic activity assays
GPI anchor phospholipase D activity can be measured using synthetic substrates or GPI-anchored proteins labeled with fluorescent or radioactive tags. These assays quantify the release of phosphatidate or the cleavage of GPI anchors. They are used to assess GPLD1 activity in serum or cell lysates.
Western blotting and immunoprecipitation
Western blotting can detect GPLD1 protein levels and its posttranslational modifications. Immunoprecipitation followed by mass spectrometry can identify GPLD1-associated proteins, such as apolipoproteins. These methods help elucidate the regulation and complex formation of GPLD1.
CRISPR-Cas9 genome editing
CRISPR-Cas9 can generate GPLD1 knockout, knock-in, or overexpression models to study its function. These models allow researchers to dissect the role of GPLD1 in GPI metabolism and disease. They are essential for validating therapeutic targets.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon GPLD1 manipulation. These approaches identify downstream pathways affected by GPI anchor cleavage. They are useful for understanding the broader impact of GPLD1 activity.
How CRISPR Can Be Used to Study GO:0004621 GPI anchor phospholipase D activity
Knockout
CRISPR-Cas9 knockout of GPLD1 can completely abolish GPI anchor phospholipase D activity, allowing researchers to study its loss-of-function effects on GPI-anchored protein localization and signaling. Knockout cell lines and animal models are valuable for validating the role of GPLD1 in metabolic and neurological phenotypes.
Point Mutation
Point mutations in the catalytic domain of GPLD1 can be introduced using CRISPR-Cas9 to dissect the enzymatic mechanism and identify critical residues. Such models help distinguish between catalytic activity and non-enzymatic functions of GPLD1.
Knock-in
Knock-in of tagged GPLD1 (e.g., FLAG or GFP) enables tracking of the enzyme's localization and interaction partners in vivo. This approach can also be used to express disease-associated GPLD1 variants.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of GPLD1 can model the elevated GPLD1 activity seen in metabolic disorders. Overexpression studies have shown altered GPI metabolism and effects on cell surface protein expression.
How EDITGENE Supports GPI anchor phospholipase D activity Research
Researchers studying GPI anchor phospholipase D activity-related genes often need to determine whether a candidate gene is causally involved in the regulation of GPI anchor cleavage, metabolic disease, or neurodegeneration. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell and animal models, enabling functional validation of GPLD1 and related genes.
Contact EDITGENE today to design your custom CRISPR model for GPI anchor phospholipase D activity research.
Frequently Asked Questions About GPI anchor phospholipase D activity
What is GPI anchor phospholipase D activity?
GPI anchor phospholipase D activity (GO:0004621) is an enzyme activity that cleaves glycosylphosphatidylinositol (GPI) anchors on proteins, releasing the protein and generating phosphatidate.
What genes are involved in GPI anchor phospholipase D activity?
The primary gene is GPLD1, which encodes GPI-specific phospholipase D. Other genes involved in GPI anchor biosynthesis include PIGA, PIGB, and PIGK.
What is the function of GPLD1?
GPLD1 catalyzes the cleavage of GPI anchors, releasing GPI-anchored proteins from cell membranes and producing phosphatidate.
How is GPI anchor phospholipase D activity measured?
It can be measured using enzymatic assays with synthetic substrates or GPI-anchored proteins, often with fluorescent or radioactive labels.
What diseases are associated with GPLD1?
GPLD1 has been linked to metabolic disorders, cardiovascular disease, aging-related memory loss, and chronic diseases.
Is GPLD1 secreted?
Yes, GPLD1 is a secreted enzyme found in serum, where it associates with apolipoprotein complexes.
Can CRISPR be used to study GPLD1?
Yes, CRISPR-Cas9 can create GPLD1 knockout, knock-in, and overexpression models to study its function.
What is the role of GPLD1 in exercise?
Exercise induces GPLD1 from the liver, which can improve brain function and neurogenesis in aged models.
How does GPLD1 affect GPI-anchored proteins?
By cleaving GPI anchors, GPLD1 releases GPI-anchored proteins from the membrane, which can alter their function and localization.
What are the synonyms for GPI anchor phospholipase D activity?
Synonyms include glycoprotein-phosphatidylinositol phosphatidohydrolase activity, glycoprotein phospholipase D activity, glycosylphosphatidyl inositol-anchor protein phospholipase D activity, and GPI-PLD activity.
Conclusion
GPI anchor phospholipase D activity (GO:0004621) is a critical enzymatic function that regulates the release of GPI-anchored proteins and generates the signaling lipid phosphatidate. Its enzyme, GPLD1, is secreted and associated with metabolic and neurological diseases, making it a promising therapeutic target. Advances in CRISPR-based models will continue to unravel the precise roles of GPLD1 in health and disease, paving the way for novel interventions.
References
- 1. Bieri G et al.. 2026. Liver exerkine reverses aging- and Alzheimer's-related memory loss via vasculature.. Cell 189(5):1499-1516.e25 PMID: 41713415
- 2. Horowitz AM et al.. 2020. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain.. Science 369(6500):167-173 PMID: 32646997
- 3. Brown D et al.. 1992. Glycosyl-phosphatidylinositol-anchored membrane proteins.. J Am Soc Nephrol 3(4):895-906 PMID: 1450366
- 4. Mann KJ et al.. 2004. Effect of glycosylphosphatidylinositol (GPI)-phospholipase D overexpression on GPI metabolism.. Biochem J 378(Pt 2):641-8 PMID: 14611645
- 5. Müller GA et al.. 2020. Upregulated phospholipase D activity toward glycosylphosphatidylinositol-anchored proteins in micelle-like serum complexes in metabolically deranged rats and humans.. Am J Physiol Endocrinol Metab 318(4):E462-E479 PMID: 31961708
- 6. Tsujioka H et al.. 1998. Posttranslational modification of glycosylphosphatidylinositol (GPI)-specific phospholipase D and its activity in cleavage of GPI anchors.. Biochem Biophys Res Commun 251(3):737-43 PMID: 9790979
- 7. Deeg MA et al.. 2001. GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex.. J Lipid Res 42(3):442-51 PMID: 11254757
- 8. Cao J et al.. 2023. The role of GPLD1 in chronic diseases.. J Cell Physiol 238(7):1407-1415 PMID: 37393554
